Keratoconus and crosslinking: pharmacokinetic considerations

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.9, Iss.12, 2013-12, pp. : 1613-1624

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development of Biosimilars—Pharmacokinetic and Pharmacodynamic Considerations

By Wang Yow-Ming Chow Andrew

Journal of Biopharmaceutical Statistics, Vol. 20, Iss. 1, 2010-01 ,pp. : 46-61

Taylor & Francis Ltd

Access to resources Recommend Favorite

Pharmacokinetic Considerations in Development of a Bioartificial Liver

By Iwata H. Ueda Y.

Clinical Pharmacokinetics, Vol. 43, Iss. 4, 2004-01 ,pp. : 211-225

Adis International

Access to resources Recommend Favorite

Pharmacokinetic Considerations in the Treatment of Childhood Epilepsy

By Gilman Jamie T.

Pediatric Drugs, Vol. 5, Iss. 4, 2003-01 ,pp. : 267-277

Adis International

Access to resources Recommend Favorite

Pharmacokinetic Considerations in the Treatment of CNS Tumours

By Motl Susannah

Clinical Pharmacokinetics, Vol. 45, Iss. 9, 2006-01 ,pp. : 871-903

Adis International

Access to resources Recommend Favorite

Pharmacokinetic considerations for antithrombotic therapies in stroke

By Apostolakis Stavros Lip Gregory YH Shantsila Eduard

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 10, 2013-10 ,pp. : 1335-1347

Informa Healthcare

Access to resources Recommend Favorite